skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Big Pharma Outlook 2026 Pharmavitae Analytics Report Extract

Big Pharma Outlook 2026 takes a decade-long look at what’s in store for the future of Big Pharma, and includes detailed, expert analysis, giving you a competitive edge in planning your pipelines of investments and development. 

This free sample of the Big Pharma Outlook 2026 report is brought to you by Datamonitor Healthcare. Datamonitor Healthcare’s timely, in-depth, interactive research and expert analysis keep you strategically aligned with developments across a range of diseases, companies, drugs, and market trends.
Big Pharma Outlook Report 2026

Read also

  • Datamonitor Healthcare: data analysis and insight, Pink Shee...

    Pharma Intelligence Podcasts

    Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa

    Topics Coronavirus $name $name Clinical Trials Blog Clinical Trials Drug Pricing

  • Datamonitor Healthcare: data analysis and insight

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: